Breast cancer is one of the leading causes of death among women worldwide. Despite therapeutic advances, conventional treatments are often limited by major side-effects and disease resistance, making it necessary to develop more targeted and effective strategies.
In this context, immunotherapy, which aims to stimulate the patient's own immune system, is attracting growing interest. While promising results have been obtained with monotherapy, the combination of immunotherapies is emerging as a way of improving treatment efficacy and overcoming resistance. This study analyses the impact of combined immunotherapies in the treatment of breast cancer.
A meta-analysis to assess the efficacy of combined immunotherapies
This study, based on a systematic review and meta-analysis of phase I to IV clinical trials, assesses the efficacy of combined immunotherapies in the treatment of breast cancer. The studies included compared the effects of combined therapies with those of a single immunotherapy, analysing two main indicators: overall survival (OS) and progression-free survival (PFS).
The results showed that combination immunotherapies significantly improved OS and PFS compared with monotherapies, confirming their potential in real-life clinical settings for breast cancer patients.
Combined immunotherapies: towards a new era in the treatment of breast cancer
This research shows that combined immunotherapies are a promising therapeutic option in the treatment of breast cancer. By targeting both tumour cells and the tumour microenvironment, these therapies offer a solution for optimising the immune response, overcoming resistance to treatment, reducing the risk of recurrence and thus prolonging patient survival. These advances also pave the way for more effective personalised treatments for breast cancer.
Last press reviews
Colon Cancer: a new therapeutic breakthrough?
Colorectal cancer (CRC) ranks among the most common and deadly cancers wor...
Clindamycin and postoperative infections: towards more effective prophylaxis?
Surgical site infections (SSIs) remain a common complication in minor surg...
A promising breakthrough in cancer cachexia treatment
Cancer cachexia is a common and severe cancer complication characterized b...